Mavrilimumab
Single intravenous infusion of Mavrilimumab 6mg/kg
Placebo
Concomitant medications included antiviral drugs relatedto COVID-19, corticosteroids, convalescent plasma, otherimmunosuppressive agents, and antimicrobial drugsrelated to non-COVID-19 infections.
COVID 19 hospitalized
Patients with documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongoing anti-pyretic use to suppress fever, hypoxia (Room air SpO2 <92% or requirement for supplemental oxygen), increased serum inflammatory marker (CRP > 5 mg/dL), severity of disease warrants inpatient hospitalization. Patients were excluded if they required mechanical ventilation.
Double-blind.
Multicenter, 7 hospitals in United States.
A trial of 60 patients was planned, but given slow enrolment, the study was stopped early toinform the natural history and potential treatment effect.
